# Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.

> **NCT03928847** · EARLY_PHASE1 · COMPLETED · sponsor: **Hal Chapman** · enrollment: 35 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** Epigallocatechin-3-gallate (EGCG)

## Key facts

- **NCT ID:** NCT03928847
- **Lead sponsor:** Hal Chapman
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-01
- **Primary completion:** 2019-05-31
- **Final completion:** 2019-05-31
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2022-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03928847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03928847, "Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03928847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*